Timothy L Wiemken1, Ruth M Carrico2, Sabra L Klein3, Colleen B Jonsson4, Paula Peyrani5, Robert R Kelley6, Stefano Aliberti7, Francesco Blasi8, Ricardo Fernandez-Gonzalez9, Gustavo Lopardo10, Julio A Ramirez11. 1. University of Louisville School of Medicine, Division of Infectious Diseases, Louisville, KY, United States; University of Louisville Clinical and Translational Research Support Unit, Louisville, KY, United States. Electronic address: tlwiem01@louisville.edu. 2. University of Louisville School of Medicine, Division of Infectious Diseases, Louisville, KY, United States. Electronic address: ruth.carrico@louisville.edu. 3. Johns Hopkins Bloomberg School of Public Health, Department of Molecular Microbiology and Immunology, Baltimore, MD, United States. Electronic address: saklein@jhsph.edu. 4. University of Louisville School of Medicine, Department of Microbiology and Immunology, Louisville, KY, United States. Electronic address: cbjons01@louisville.edu. 5. University of Louisville School of Medicine, Division of Infectious Diseases, Louisville, KY, United States; University of Louisville Clinical and Translational Research Support Unit, Louisville, KY, United States. Electronic address: p0peyr01@louisville.edu. 6. University of Louisville School of Medicine, Division of Infectious Diseases, Louisville, KY, United States; University of Louisville Clinical and Translational Research Support Unit, Louisville, KY, United States. Electronic address: rrkell01@louisville.edu. 7. Department of Health Science, University of Milan Bicocca, Clinica Pneumologica, AO San Gerardo, Via Pergolesi 33, Monza, Italy. Electronic address: stefano.aliberti@unimib.it. 8. Dipartimento di Fisiopatologia e dei Trapianti, University of Milan, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, Milan, Italy. Electronic address: francesco.blasi@unimi.it. 9. Pulmonary Training Program, San Juan City Hospital, Puerto Rico. Electronic address: rfernandezg74@gmail.com. 10. Department of Infectious Diseases, Hospital Profesor Bernardo Houssay, Vicente López, Buenos Aires, Argentina. Electronic address: glopardo@intramed.net. 11. University of Louisville School of Medicine, Division of Infectious Diseases, Louisville, KY, United States; University of Louisville Clinical and Translational Research Support Unit, Louisville, KY, United States. Electronic address: jarami01@louisville.edu.
Abstract
BACKGROUND: The effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) to prevent hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia (SpCAP) is controversial. Recent literature suggests that vaccine effectiveness may be influenced by sex. In this study, we define the effectiveness of prior PPV23 vaccination for the prevention of hospitalizations due to SpCAP, and evaluate the impact of sex on this effectiveness. METHODS: This was a nested case-control study from the CAPO international cohort study database. SpCAP was defined as CAP plus S. pneumoniae identified in blood, bronchoalveolar lavage, sputum, or urinary antigen. Vaccination with PPV23 prior to hospitalization was defined as documented in the medical record. A propensity score-weighted logistic regression model was used to calculate odds ratios. The adjusted vaccine effectiveness (aVE) was calculated as 1-adjusted odds ratio. RESULTS: From a total of 2688 elderly adult hospitalized patients with CAP, SpCAP was identified in 279 (10%). The overall aVE was 37% (95% CI: 10.1-55.4%, P=0.01). For males, the aVE was 34% (95% CI:-1.0% to 57.3%, P=0.06). For females the aVE was 68% (95% CI: 40.3-83.0%, P=0.001). CONCLUSIONS: PPV23 protects elderly patients from hospitalization due to SpCAP, but female sex drives the effectiveness. Future analysis of vaccine trials should consider the importance of sex as a stratification factor.
BACKGROUND: The effectiveness of the 23-valent pneumococcalpolysaccharide vaccine (PPV23) to prevent hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia (SpCAP) is controversial. Recent literature suggests that vaccine effectiveness may be influenced by sex. In this study, we define the effectiveness of prior PPV23 vaccination for the prevention of hospitalizations due to SpCAP, and evaluate the impact of sex on this effectiveness. METHODS: This was a nested case-control study from the CAPO international cohort study database. SpCAP was defined as CAP plus S. pneumoniae identified in blood, bronchoalveolar lavage, sputum, or urinary antigen. Vaccination with PPV23 prior to hospitalization was defined as documented in the medical record. A propensity score-weighted logistic regression model was used to calculate odds ratios. The adjusted vaccine effectiveness (aVE) was calculated as 1-adjusted odds ratio. RESULTS: From a total of 2688 elderly adult hospitalized patients with CAP, SpCAP was identified in 279 (10%). The overall aVE was 37% (95% CI: 10.1-55.4%, P=0.01). For males, the aVE was 34% (95% CI:-1.0% to 57.3%, P=0.06). For females the aVE was 68% (95% CI: 40.3-83.0%, P=0.001). CONCLUSIONS: PPV23 protects elderly patients from hospitalization due to SpCAP, but female sex drives the effectiveness. Future analysis of vaccine trials should consider the importance of sex as a stratification factor.
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Gerhard Falkenhorst; Cornelius Remschmidt; Thomas Harder; Eva Hummers-Pradier; Ole Wichmann; Christian Bogdan Journal: PLoS One Date: 2017-01-06 Impact factor: 3.240
Authors: Amy Schneeberg; Julie A Bettinger; Shelly McNeil; Brian J Ward; Marc Dionne; Curtis Cooper; Brenda Coleman; Mark Loeb; Ethan Rubinstein; Janet McElhaney; David W Scheifele; Scott A Halperin Journal: BMC Public Health Date: 2014-05-12 Impact factor: 3.295